Biomedical company Femasys has secured CE mark certification and Health Canada approval for FemVue MINI, a compact solution for assessing fallopian tubes.
Designed for in-office use, the FemVue MINI device offers the same efficacy as the original FemVue but in a more environmentally friendly package.
Go deeper with GlobalData
The innovation aligns with Femasys’ commitment to sustainable healthcare solutions, as the device’s smaller size reduces its environmental footprint.
Femasys’ initiative to incorporate eco-conscious practices extends across its product lines.
The FemVue MINI is part of this broader effort to integrate impactful environmental programmes into the company’s offerings.
Femasys founder, president, and CEO Kathy Lee-Sepsick said: “Our mission at Femasys has always been to develop cutting-edge technology that are safe, affordable, and accessible to address critical needs in women’s health.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“With the FemVue MINI, we are advancing an equally effective solution in a smaller footprint that is aligned with our initiative to be environmentally conscious demonstrating our commitment to sustainability.”
FemVue is an FDA-cleared product that creates natural contrast for real-time ultrasound evaluation of fallopian tubes in a gynaecologist’s office.
It is a safer and less expensive alternative to traditional radiology exams.
FemVue is also approved for use in Canada and Europe.
In June 2024, Femasys obtained the EU Medical Device Regulation (MDR) certificate and CE Mark certification for four women’s health products.
The products include FemaSeed, FemVue, FemCerv and FemCath and are developed for women’s reproductive health.
The development paves the way for the company to commence commercialisation efforts for the products within the European market.
